NCT00934882 - Study to Determine Safety, Pharmacokinetics, Pharmacodynamics of BAY73-4506 in Combination With mFOLFOX6 or FOLFIRI | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

April 30, 2012

Study Completion Date

April 30, 2012

Conditions

Colorectal Neoplasms

Interventions

DRUG

Regorafenib (BAY73-4506)

Administration of the multi-kinase inhibitor BAY73-4506 (160 mg once daily from Day 4 to Day 10 and from Day 18 to Day 24) as oral treatment in combination with the chemotherapy regimen mFOLFOX6 or FOLFIRI in patients with metastatic Colorectal Cancer

Trial Locations (7)

26133

Oldenburg

44625

Herne

50937

Cologne

68167

Mannheim

69120

Heidelberg

79106

Freiburg im Breisgau

01307

Dresden